1. Home
  2. ALT vs DXYZ Comparison

ALT vs DXYZ Comparison

Compare ALT & DXYZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • DXYZ
  • Stock Information
  • Founded
  • ALT 1997
  • DXYZ N/A
  • Country
  • ALT United States
  • DXYZ
  • Employees
  • ALT N/A
  • DXYZ N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • DXYZ
  • Sector
  • ALT Health Care
  • DXYZ
  • Exchange
  • ALT Nasdaq
  • DXYZ Nasdaq
  • Market Cap
  • ALT 292.8M
  • DXYZ 334.3M
  • IPO Year
  • ALT N/A
  • DXYZ 2024
  • Fundamental
  • Price
  • ALT $3.61
  • DXYZ $30.19
  • Analyst Decision
  • ALT Strong Buy
  • DXYZ
  • Analyst Count
  • ALT 6
  • DXYZ 0
  • Target Price
  • ALT $18.20
  • DXYZ N/A
  • AVG Volume (30 Days)
  • ALT 3.5M
  • DXYZ N/A
  • Earning Date
  • ALT 08-15-2025
  • DXYZ N/A
  • Dividend Yield
  • ALT N/A
  • DXYZ N/A
  • EPS Growth
  • ALT N/A
  • DXYZ N/A
  • EPS
  • ALT N/A
  • DXYZ N/A
  • Revenue
  • ALT $20,000.00
  • DXYZ N/A
  • Revenue This Year
  • ALT N/A
  • DXYZ N/A
  • Revenue Next Year
  • ALT $346,228.97
  • DXYZ N/A
  • P/E Ratio
  • ALT N/A
  • DXYZ N/A
  • Revenue Growth
  • ALT N/A
  • DXYZ N/A
  • 52 Week Low
  • ALT $2.90
  • DXYZ N/A
  • 52 Week High
  • ALT $11.16
  • DXYZ N/A
  • Technical
  • Relative Strength Index (RSI)
  • ALT 34.75
  • DXYZ N/A
  • Support Level
  • ALT $3.58
  • DXYZ N/A
  • Resistance Level
  • ALT $4.39
  • DXYZ N/A
  • Average True Range (ATR)
  • ALT 0.19
  • DXYZ 0.00
  • MACD
  • ALT -0.00
  • DXYZ 0.00
  • Stochastic Oscillator
  • ALT 4.65
  • DXYZ 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About DXYZ Destiny Tech100 Inc. Common Stock

Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.

Share on Social Networks: